Active Biotech AB - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Active Biotech AB - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Active Biotech AB - Product Pipeline Review - 2014', provides an overview of the Active Biotech AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Active Biotech AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Active Biotech AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Active Biotech AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Active Biotech AB's pipeline products

Reasons to buy

- Evaluate Active Biotech AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Active Biotech AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Active Biotech AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Active Biotech AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Active Biotech AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Active Biotech AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Active Biotech AB Snapshot 5
Active Biotech AB Overview 5
Key Information 5
Key Facts 5
Active Biotech AB - Research and Development Overview 6
Key Therapeutic Areas 6
Active Biotech AB - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Active Biotech AB - Pipeline Products Glance 12
Active Biotech AB - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Active Biotech AB - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Active Biotech AB - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Active Biotech AB - Drug Profiles 15
tasquinimod 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
naptumomab estafenatox 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
paquinimod 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ISI 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Active Biotech AB - Pipeline Analysis 21
Active Biotech AB - Pipeline Products by Target 21
Active Biotech AB - Pipeline Products by Route of Administration 22
Active Biotech AB - Pipeline Products by Molecule Type 23
Active Biotech AB - Pipeline Products by Mechanism of Action 24
Active Biotech AB - Recent Pipeline Updates 25
Active Biotech AB - Dormant Projects 29
Active Biotech AB - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
ABR-224050 30
Active Biotech AB - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Active Biotech AB, Key Information 5
Active Biotech AB, Key Facts 5
Active Biotech AB - Pipeline by Indication, 2014 7
Active Biotech AB - Pipeline by Stage of Development, 2014 8
Active Biotech AB - Monotherapy Products in Pipeline, 2014 9
Active Biotech AB - Out-Licensed Products in Pipeline, 2014 10
Active Biotech AB - Out-Licensed Products/ Combination Treatment Modalities, 2014 11
Active Biotech AB - Phase III, 2014 12
Active Biotech AB - Phase II, 2014 13
Active Biotech AB - Preclinical, 2014 14
Active Biotech AB - Pipeline by Target, 2014 21
Active Biotech AB - Pipeline by Route of Administration, 2014 22
Active Biotech AB - Pipeline by Molecule Type, 2014 23
Active Biotech AB - Pipeline Products by Mechanism of Action, 2014 24
Active Biotech AB - Recent Pipeline Updates, 2014 25
Active Biotech AB - Dormant Developmental Projects,2014 29
Active Biotech AB - Discontinued Pipeline Products, 2014 30
Active Biotech AB, Subsidiaries 31